CELZ: Creative Medical Technology Holdings, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 10.47
Enterprise Value ($M) 4.23
Book Value ($M) 6.56
Book Value / Share 3.75
Price / Book 1.60
NCAV ($M) 6.00
NCAV / Share 3.43
Price / NCAV 1.75

Profitability (mra)
Return on Invested Capital (ROIC) -0.81
Return on Assets (ROA) -0.50
Return on Equity (ROE) -0.51

Liquidity (mrq)
Quick Ratio 19.12
Current Ratio 19.13

Balance Sheet (mrq) ($M)
Current Assets 6.33
Assets 6.89
Liabilities 0.33
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)
Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)
2024-08-09 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One)
2024-04-29 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Mark One)
2024-03-22 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One)

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-21 24,380 97,978 24.88
2025-02-20 113,725 315,378 36.06
2025-02-19 100,507 281,892 35.65
2025-02-18 40,817 108,711 37.55

(click for more detail)

Similar Companies
CDTX – Cidara Therapeutics, Inc. CDXC – ChromaDex Corporation
CELU – Celularity Inc. CGEN – Compugen Ltd.
CING – Cingulate Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.